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INTRODUCTION 
 
Pernicious anemia (PA) is the end-stage of autoimmune gastritis (AG), likely as 
a consequence of long-standing H pylori infection. The active infectious process 
is gradually replaced by an autoimmune disease terminating in a burned-out 
infection and the irreversible destruction of the gastric body mucosa (Toh et al, 
1998; Bergman et al, 2001). The autoimmune origin of PA is further supported 
by the presence of parietal cell and/or intrinsic factor autoantibodies and the 
frequent association with other autoimmune disorders, such as autoimmune 
thyroid disease, type I diabetes, and vitiligo (Toh et al, 1998; De Block et al, 
2008; Lahner et al, 2008).  
PA is a macrocytic anemia due to cobalamin (vitamin B12) deficiency, which, in 
turn, is the result of deficiency of intrinsic factor, a protein that binds avidly to 
dietary vitamin B12 and promotes its transport to the terminal ileum for 
absorption. The deficiency of intrinsic factor is a consequence of the presence of 
atrophic gastritis resulting in the destruction of the oxyntic mucosa, and, thus, 
the loss of parietal cells, which normally produce chlorhydric acid as well as 
intrinsic factor (Annibale et al, 2011; Babior et al, 1998). The term PA is 
sometimes used as synonym for cobalamin deficiency or for macrocytic anemia, 
but to avoid ambiguity, PA should be reserved for conditions resulting from 
impaired secretion of intrinsic factor and atrophy of oxyntic mucosa. However, 
differential diagnosis may sometimes be challenging due to the limit of 
available diagnostic tools.  
 
Pernicious anemia: epidemiology and clinical presentation 
The clinical presentation of PA is often insidious for various reasons. The onset 
and progression of PA are very slow. As a consequence, often patients are not 
aware of their symptoms related to anemia, because over time they had got 
used to them. In many such cases, the underlying disease may not be suspected 
until a complete red blood count has been performed. However, patients with 
PA may seek medical advice due to aspecific symptoms related to the presence 
of anemia per se, such as weakness, asthenia, decreased mental concentration, 
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headache, and, especially in elderly patients, cardiological symptoms such as 
palpitations and chest pain (Annibale et al, 2011; Babior et al, 1998). Less 
frequently, PA may present with neurological symptoms, such as paresthesias, 
unsteady gait, clumsiness and in some cases spasticity. Indeed, vitamin B12 
deficiency may cause peripheral neuropathy and lesions in the posterior and 
lateral columns of the spinal cord (subacute combined degeneration) and in the 
cerebrum, and these lesions progress from demyelisation to axonal 
degeneration and eventual neuronal death. Moreover, there is a growing body 
of evidence on the relationship between cobalamin deficiency and dementia 
(10). The early recognition of these symptoms is very important, because the 
neurological lesions may not be reversed after replacement therapy with 
vitamin B12  and patients with PA generally respond favorably to supplemental 
B12 treatment, especially if PA is diagnosed early in the course of the disease 
(Werder, 2010).   
Finally, the onset of PA may be observed in patients under medical treatment 
for other autoimmune conditions frequently associated with PA, such as 
autoimmune thyroid disease, type I diabetes, and vitiligo, as part of the 
autoimmune polyendocrine syndromes (Eisenbarth & Gottlieb, 2004). 
Albeit the primum movens of PA is AG, less frequently the disease is suspected 
due to symptoms of the gastrointestinal tract. The reason for the apparent 
paradox may lay in the fact that AG is associated with hypochlorhydria, and 
symptoms of the upper gastrointestinal tract are often related to the presence of 
chlorhydric acid. However, hypochlorhydria itself may cause impaired gastric 
emptying, eventually leading to dyspeptic symptoms such as epigastric 
discomfort, postprandial bloating and fullness, and early satiety (Annibale et al, 
2005; Tosetti et al, 2000). Often the awareness and/or the concern about upper 
gastrointestinal symptoms and/or neurological symptoms are not sufficient to 
seek medical advice for this reason and specific data about clinical presentation 
in PA are scarce. In previous works performed on 177 consecutively diagnosed 
PA patients, dyspeptic symptoms were complained by 27.7%, and neurological 
symptoms, such as paresthesias, were present in 18.6% of patients, suggesting 
that the presence of these symptoms should be related to the possible 
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subclinical presence of PA (Annibale et al, 2000; Marignani et al, 1999). 
Anyway, in a very recent analysis PA patients were more frequently reporting 
no gastrointestinal symptoms, which were however present in half of them 
(47.5%) (Carabotti et al, 2017). 
In a previous work, autoimmune thyroid disease showed a prevalence of nearly 
40% in atrophic body gastritis patients (Lahner et al, 2008). The diagnosis of a 
concomitant presence of autoimmune thyroiditis and PA may have an 
important clinical implication, in particular in those patients who require 
replacement therapy with thyroxine, because patients with an impaired acid 
secretion may present thyroxine malabsorption requiring an increased dose of 
the drug (Lahner et al, 2014), and in patients with PA an associated 
hypochlorhydria is always present due to the loss of oxyntic mucosa (Annibale 
et al, 2011).   
Useful information about in whom PA may be suspected, may derive also from 
epidemiological data. According to the older literature, PA is thought to be 
particularly common among individuals of Scandinavian, English, and Irish 
ancestry, while it appears to be much less common in Caucasians of Italian or 
Greek origin (Friedlander, 1934); in recent years, the disease have been reported 
in black and Latin-American subjects (Carmel, 1996; Carmel et al, 1978). In the 
so-called high-risk groups, about 9 new cases are detected per 100,000 
population per year, and about 0.13% of the population is affected (Pedersen et 
al, 1969). The only more recent population survey reported that 1.9% of persons 
more than 60 years old has undiagnosed PA (Carmel, 1996). 
A female preponderance ranging from 1.7 to 2.0:1 has been reported in white 
subjects (Babior, 1998). This gender distribution was confirmed in the more 
recent population survey of persons more than 60 years old conducted in 
California, in which the prevalence of PA was 2.7% in women and 1.4% in men 
(Carmel, 1996).  
Regarding the age, PA is frequently described as a disease of adults >60 years of 
age (Carmel, 1996). In spite of this, some data challenged the common notion 
that PA is a disease of the elderly (Hershko et al, 2006), suggesting that in 
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clinical practice PA is probably underdiagnosed not only in elderly but also in 
younger patients. 
Considering the clinical scenario, it may be reminded that (i) iron deficiency is a 
consequence of achlorhydria and may precede the development of PA (1) and 
(ii) iron deficiency may be present in concomitance with PA (Carmel et al, 
1986). It has been shown that stratification by age cohorts from younger than 20 
years to older than 60 years of patients with AG identified by hypergastrinemia 
and positive parietal cell antibodies showed a regular and progressive increase 
in mean corpuscular volume and levels of ferritin and gastrin and a decrease in 
vitamin B12 levels, whereas the prevalence of H pylori infection decreased from 
more than 80% at age younger than 20 years to 12.5% at age older than 60 years 
(Hershko et al, 2006). These findings support the idea that PA seems to be a 
disease starting many years before the establishment of clinical vitamin B12 
deficiency.  
 
Pernicious anemia: diagnosis and management 
PA is defined as the presence of a hemoglobin concentration <13 g/dL for men 
and <12 g/dL for women (WHO, 2001), mean corpuscular volume (MCV) >100 
fL (9), low levels of cobalamin (vitamin B12) (Babior, 1998), together with the 
concomitant presence of AG and intrinsic factor deficiency. 
Thus, by definition, PA is associated with AG, and strict diagnostic criteria for 
AG are based on the histological evidence of gastric body mucosal atrophy and 
ECL hyperplasia associated with hypochlorhydria to pentagastrin stimulation 
(Lee et al, 2002). Increased levels of fasting gastrin and decreased levels of 
Pepsinogen I are well accepted serological markers suggesting the presence of 
oxyntic mucosa damage (Kekki et al, 1991; Vaananen et al, 2003), which should 
be confirmed, however, by appropriate histological sampling of gastric body 
mucosa to definitively diagnose AG. 
As far as regards gastric mucosa histology, corpus-restricted atrophy with a 
spared antrum is a classical and indispensable feature required for the 
diagnosis of PA. As reported in a previous review (Lahner & Annibale, 2001), in 
about 50% of PA patients antral mucosa is not spared, and in about 27% of PA 
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patients a concomitant antral atrophic gastritis may be observed. These data 
strongly suggest that an extension of gastritis to the gastric antrum does not 
necessarily exclude the diagnosis of PA and the presence of gastric 
autoimmunity. Also the determination of ECL cells hyperplasia is considered 
helpful in the histological diagnosis of AG associated with PA, because the 
presence of this histological change indirectly proves the presence of 
hypochlorhydria, which leads to hypergastrinemia which, in turn, is a trophic 
factor for ECL cells leading to their hyperplasia and eventually to the 
development of gastric carcinoids (Lahner et al, 2009). 
Intrinsic factor deficiency would be proven by the now obsolete Schilling test: 
in order to confirm that the cobalamin deficiency is the result of intestinal 
malabsorption due to intrinsic factor deficiency, urinary excretion of orally 
administered vitamin B12 is low, and is increased by administration of vitamin 
B12 together with intrinsic factor. Unfortunately, the availability of this test is 
vanishing due to problems related to its radioactive reagents. In alternative, a 
gastric juice intrinsic factor assay has been proposed, which assesses the gastric 
intrinsic factor output after pentagastrin stimulation considering a value lower 
than 200 U/ h as diagnostic for PA (Cattan, 2011). However, probably because 
needing gastric tubage, this invasive test it has not earned wide popularity.  
Therefore, in clinical practice, the presence of intrinsic factor deficiency may not 
be definitely proven and increasing reliance is placed on the detection of 
intrinsic factor antibodies for the diagnosis of PA, which are viewed as useful 
markers of this disease (Toh et al, 2007). Earlier studies reported the positivity 
to intrinsic factor antibodies in 40-60% of patients with PA (Ungar et al, 1967; 
Davidson et al, 1989), rising to 60-80% with increasing duration of disease 
(Carmel, 1992). In more recent years, the diagnostic performance of intrinsic 
factor and parietal cell antibodies has been assessed in patients with atrophic 
body gastritis with respect to cobalamin deficiency by using a novel ELISA 
assay (Lahner et al, 2009): in PA patients, intrinsic factor antibodies achieved a 
sensitivity and a specificity of 37% and 100%, respectively, and parietal cell 
antibodies yielded a sensitivity and a specificity of 81.5% and 90.3%, 
respectively. The combined assessment of both autoantibodies significantly 
 7 
increased their diagnostic performance, yielding a 73% sensitivity for PA, while 
maintaining a 100% specificity. Thus, by combining the assessment of intrinsic 
factor and parietal cell autoantibodies the diagnostic performance of these 
surrogate markers for PA may notably be improved. Further, beyond as a 
specific hallmark of PA, the positivity to intrinsic factor and parietal cell 
antibodies may be interpreted also as an expression of oxyntic mucosa damage, 
because the increasing histological score of body mucosa atrophy correlated 
positively with the titer of both antibodies (Annibale et al, 2001; Annibale et al, 
2005). The anemia seems to develop longitudinally over many years in anti-
parietal cell antibodies-positive patients, symptomless, slowly promoting 
atrophy of the gastric mucosa and parietal cells (Rusak et al, 2016). In a very 
recent work conducted on atrophic gastritis patients, positivity to both ATP4A 
and ATP4Bautoantibodies resulted to be closely associated with atrophic body 
gastritis, suggesting that these assays should be valuable screening tools for 
detecting biomarkers of damaged atrophic oxyntic mucosa (Lahner et al, 2017). 
Notwithstanding, an accurate differential diagnosis of other causes of 
cobalamin deficiency is mandatory. As previously reviewed (Lahner & 
Annibale, 2009), cobalamin deficiency may be caused by other causes of 
impaired absorption in the stomach or in the intestine, such as gastrectomy, 
ileal disease or resection, or by decreased intake due to vegetarianism. Among 
maldigestion, there are very rare cases related to severe pancreatic 
insufficiency, but more interesting is the recent evidence of maldigestion of 
dietary cobalamin in patients with corpus predominant H pylori gastritis 
leading to impaired acid secretion and consequent increased intragastric pH 
(Carmel et al, 1994; Cohen et al, 2000). In fact, dietary cobalamin is bound to 
salivary proteins, which need to be cleaved in presence of chlorhydric acid 
before it can be bound to intrinsic factor and be absorbed in the terminal ileum 
(Lahner & Annibale, 2009). In these cases of dietary cobalamin maldigestion 
Schilling test would be normal, indicating that cobalamin deficiency is not due 
to intrinsic factor deficiency. Without performing a Schilling test, it may be 
challenging to discriminate between the presence of PA and the presence of 
maldigestion of dietary cobalamin. However, from a practical point of view, the 
 8 
clinical management of these two groups of patients is similar. Further, an 
accurate differential diagnosis should be carried out also for macrocytic anemia, 
which may underly other causes such as folate deficiency and myelodysplasia 
(Lahner & Annibale, 2009), and the assessment of serum homocysteine levels is 
be helpful. In this context, it should be kept in mind that in order to diagnose 
vitamin B12 deficency, total vitamin B12 measurement is used cost effectively as 
the parameter of choice, but it has limited sensitivity and specificity, especially 
in persons with vitamin B12 concentrations in the lower reference range (<400 
pmol/L). In alternative, modern biomarkers for early diagnosis of vitamin B12 
deficency, as holotranscobalamin (holoTC), also known as active B12, and 
methyl malonic acid as a functional B12 marker have been proposed (Herrmann 
& Obeid, 2008). Figure 1 shows the diagnostic clues for PA (Annibale et al, 
2011). 
The clinical management of patients with PA concerns two different aspects. 
First, the treatment of cobalamin deficiency and the monitoring of onset of iron 
deficiency. Second, the surveillance to early detect long-term consequences of 
PA, such as gastric cancer, carcinoids and, eventually, other type of cancers, 
with this last topic being the object of the present work. 
The cobalamin replacement treatment is able to correct the anemia, whereas the 
neurological complications may be corrected only if the replacement treatment 
is given soon after their onset. However, the practice of giving cobalamin as an 
intramuscular injection has several drawbacks, because injections can be 
painful, difficult to provide for elderly or alone-living patients, and expensive if 
provided by health professionals. Thus, at least since the early 90ies, the 
usefulness of oral cobalamin treatment in PA has been debated (Hathcock et al, 
1991; Lederle, 1991). According to a systematic review conducted by French 
hematologists (Lederle, 1991), several prospective studies (n= 4), prospective 
randomized studies (n= 3) and a systematic review by the Cochrane group 
(n=1) provide evidence that oral cobalamin therapy may adequately treat 
cobalamin deficiency, particularly hematological abnormalities or 
manifestations. These studies suggest that at least 1000 µg/day of oral 
cyanocobalmin are needed for pernicious anemia and a mean daily dose of 250 
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µg for food-cobalamin malabsorption, confirming the previously reported 
efficacy of oral cobalamin treatment in adult and elderly patients. 
 
Pernicious anemia between autoimmunity and H. pylori infection 
Atrophic body gastritis associated with PA is often called autoimmune gastritis 
or type A gastritis, which is defined as a type of chronic atrophic gastritis 
restricted to the body mucosa, characterized by a severe, diffuse atrophy of the 
oxyntic glands and hypochlorhydria, and a normal antral mucosa. Another 
classical histological feature of AG is the absence of H pylori on gastric mucosal 
biopsies (Lee et al, 2002). It is now accepted, that long-standing H pylori 
infection is able to induce atrophy of the gastric mucosa, and H pylori is 
considered the main causative agent of multifocal atrophic gastritis, in which 
the antrum is almost invariably involved (Peterson et al, 2002). Thus, AG is 
generally considered a separate entity from H pylori–related atrophic gastritis, 
mainly because the prevalence of H pylori infection in patients with severe AG 
and PA has been described to be low (Varis et al, 1993; Annibale et al, 2000). 
However, in the last years, the question has been raised whether H pylori may 
be implicated in the pathogenesis of AG, and, as basic mechanism for the 
induction of gastric autoimmunity by H pylori infection, molecular mimicry has 
been proposed (D’Elios et al, 2004; Appelmelk et al, 1998; Field et al, 2005). 
Molecular mimicry is defined as the possibility that sequence similarities 
between foreign and self-peptides are sufficient to result in the cross-activation 
of autoreactive T or B cells by pathogen-derived peptides and is a phenomenon 
associated with some pathogens where the antigens evoking an immune 
response have enough similarity to the body's own proteins to cause an 
autoimmune reaction, such as in rheumatoid arthritis, mediated by cross-
reactive T cells and/or circulating antibodies. In fact, gastric H+/K+-ATPase has 
been recognized as the major autoantigen in experimental and human AG (Toh 
et al, 1992; Ma et al, 1994; Claeys et al, 1998), and autoreactive gastric CD4+T 
cells recognizing H+, K+-ATPase and H pylori antigens have been recently 
described in AG (Amedei et al, 2003; D’Elios et al, 2005). Thus, PA and AG seem 
to be an example of pathogen (H pylori)-induced-organ-specific autoimmunity, 
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in which genetical susceptibility plays an important role in relation to the loss of 
immunological tolerance (D’Elios et al, 2005). In fact, the immunological basis of 
molecular mimicry lies in the recognition by the T-cell antigen receptor of an 
antigenic peptide bound to a human leukocyte antigen (HLA) molecule on the 
surface on an antigen-presenting cell, and inappropriate activation of T cells 
may occur as a result of the up-regulation of HLA molecules in genetically 
susceptible individuals (Albert et al, 1999). A specific HLA-DR pattern has been 
suggested in PA patients several years ago (Ungar et al, 1981), and, more 
recently, blocking experiments with anti-DR and anti-DQ antibodies could 
show that DR probably represents the HLA restriction element in AG (Amedei 
et al, 2003).   
The presence of H pylori infection was diagnosed by histology in up to 30% 
(median 11%), but by serology (IgG) in up to 51% (median 20.5%) of PA 
patients. It is well known that the diagnosis of H pylori infection may be difficult 
in patients with AG. H pylori may disappear over time due to the hostile gastric 
microenvironment, and past infection may be evidenced by positivity to H 
pylori serology in a large majority of patients with AG or PA (Annibale et al, 
2000; Valle et al, 1999; Annibale et al, 2001). Another paper reported that the 
seropositivity against H pylori antigens may be evidenced in a very high 
percentage of patients with AG by using an ad hoc immunoblotting (Annibale et 
al, 2007): in this study 47.8% of AG patients had PA and all but two of them 
presented seropositivity against H pylori antigens including CagA and VacA. As 
far as regards histological features of the gastric body, in the vast majority of PA 
patients (>70%) this disorder is associated with severe body atrophy and the 
presence of intestinal metaplasia. Irrespective from the presence of H pylori 
infection, in about half of PA patients the gastric antrum is involved, and in 
about one third even by an antral atrophic gastritis, whose presence is strongly 
related to H pylori infection (Peterson et al, 2002). This observation challenges 
the widely accepted notion that PA occurs exclusively in association with the 
classical histological feature of corpus-restricted atrophic gastritis. All these 
data taken together supports the idea that long-standing H pylori infection 
probably plays an important role in many genetically susceptible PA patients, 
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in whom the active infectious process has been gradually replaced by an 
autoimmune process run by autoreactive gastric CD4+T cells recognizing H+, 
K+-ATPase and H pylori antigens, finally terminating in a burned-out infection 
and the irreversible destruction of the gastric body mucosa. The failure to 
evidence H pylori infection in some of these individuals does not necessarily 
argue against the role of the bacterium in these patients but, more likely 
indicates that a point of no return may be reached beyond which the 
autoimmune process may no longer require the continued presence of the 
inducing pathogen (Rose et al, 1993). 
 
Pernicious anemia, autoimmune atrophic gastritis and risk of gastric 
neoplasms 
Gastric cancer is still the fourth most common cancer worldwide and the 
second cause of cancer-related death (Lahner et al, 2015). A varying progression 
rate of atrophic gastritis to gastric cancer up to 2% per year has been reported at 
follow-up periods ranging from 1 to 16 years (Whiting et al, 2002; Dinis-Ribeiro 
et al, 2004; Vannella et al, 2010). A recent systematic review showed in atrophic 
gastritis patients with pernicious anemia a pooled gastric cancer incidence-rate 
of 0.3% person-year and an estimated 7-fold relative risk of gastric cancer 
(Vannella et al, 2013).  
In patients with atrophic gastritis also type 1 gastric carcinoids may arise. Data 
on long-term incidence of type 1 gastric carcinoids are scanty (Annibale et al, 
2001; Kokkola et al, 1998; Sjoblom et al, 1988). A recent cohort study reported an 
annual incidence rate for type 1 gastric carcinoid of 0.4% (Vannella et al, 2011), 
while an older study reported an annual incidence of 2%, observing 8 new cases 
of type 1 gastric carcinoids in 416 patient-year (Kokkola et al, 1998). In the 
above cited study, pernicious anemia was present in almost 50% of patients 
with type 1 gastric carcinoids (Vannella et al, 2011), while previous studies 
included exclusively patients with this condition (Kokkola et al, 1998; Sjoblom 
et al, 1988; Sjoblom et al, 1993; Armbrecht et al, 1990; Stockbrugger et al, 
1983).In patients with atrophic gastritis, the need and cost-effectiveness of 
regular endoscopic follow-up for gastric cancer surveillance is not definitely 
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established. Recent European guidelines recommend a scheduled surveillance 
for gastric cancer for those patients who have extensive – i.e. both antrum and 
gastric body –atrophic gastritis or intestinal metaplasia (Dinis-Ribeiro et al, 
2012). However these guidelines are not addressed to patients with pernicious 
anemia, as corpus-restricted atrophic gastritis with antrum-spared, typically 
present in pernicious anemia patients, is not considered to be part of the 
precancerous cascade described by Correa (Correa et al, 1992). According to the 
data reported, different clinical management of atrophic gastritis patients with 
or without pernicious anemia does not seem to be justified, raising questions 
whether these recommendations should include also pernicious anemia 
patients.  
With regard to surveillance for type 1 gastric carcinoids, indications are even 
more uncertain. A recent study on endoscopic management of these tumours, 
reported that for atrophic gastritis patients without recurring type 1 gastric 
carcinoids, endoscopic controls might be planned yearly in the early follow-up, 
but can probably become less intensive with endoscopic controls every 4 years 
according to atrophic gastritis screening for gastric cancer risk (Merola et al, 
2011). To better evaluate the value of surveillance in atrophic gastritis patients 
and establish follow-up frequencies, more precise data on the occurrence of 
gastric neoplastic lesions, preferably obtained in large prospective studies with 
adequate follow-up, are needed (de Vries et al, 2007).  
The combined risk of gastric cancer and carcinoids together has been 
investigated many years ago limited to pernicious anemia patients (Kokkola et 
al, 1998; Sjoblom et al, 1988). A recent study (Lahner et al, 2015) investigated in 
a prospective cohort of patients with atrophic gastritis the occurrence of gastric 
cancer and carcinoids at long-term follow-up from 4 years upwards. In this 
study a total of 200 atrophic gastritis patients from a prospective cohort (67% 
females, median age 55 years) with a follow-up of 7.5 (range 4-23.4) years were 
included.  Follow-up gastroscopies at 4-years intervals were performed. The 
results of this study showed that, overall, 22 gastric neoplastic lesions were 
detected (crude incidence 11%). Gastric cancer was diagnosed in 4 patients at a 
median follow-up of 7.2 years (crude incidence 2%). Eleven type I-gastric 
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carcinoids were detected at a median follow-up of 5.1 years (crude incidence of 
5.5%). In 7 patients, 6 low-grade and 1 high-grade dysplasia were found. The 
annual incidence rates person-year were 0.25%, 0.43%, and 0.68% for gastric 
cancer, dysplasia, and type 1 gastric carcinoids, respectively. From this study 
emerged that in atrophic gastritis patients at long-term follow-up an annual 
incidence rate of 1.36% person-year for gastric neoplastic lesions and that the 
incidence rates of gastric cancer and type 1 gastric carcinoid were not different 
(p=0.07), indicating that atrophic gastritis patients are similarly exposed to both 
risks (Lahner et al, 2015). According to Globocan 2012, the annual incidence rate 
for gastric cancer in the general Italian population is estimated to be 0.004% 
(GLOBOCAN, 2012). This study thus provides further evidence confirming the 
increased risk for gastric cancer in atrophic gastritis. The presence of pernicious 
anemia is associated with gastric carcinoids but not with gastric cancer, as 
survival free of carcinoids is significantly shorter in patients with pernicious 
anemia.   
The patients’ features associated with gastric cancer and type 1 gastric 
carcinoids are different, keeping in step with the different pathogenetic 
mechanisms of these two type of tumors (Delle Fave et al, 2012). The occurrence 
of type 1 gastric carcinoids is mainly associated with features of autoimmune 
gastritis as pernicious anemia and positivity to gastric autoantibodies. Gastric 
cancer, instead, is associated with the presence of H. pylori in the corporal 
mucosa (HR  8) (Lahner et al, 2015) keeping in step with the concept of corpus-
predominant gastritis as observed by Uemura more than ten years ago that H. 
pylori positive patients and those with severe gastric atrophy, corpus-
predominant gastritis or intestinal metaplasia are at increased risk for gastric 
cancer  (Uemura et al, 2001). The presence of pernicious anemia is associated 
with gastric carcinoids but not with gastric cancer, as survival free of carcinoids 
is significantly shorter in patients with pernicious anemia.   
Atrophic patients are exposed to a double risk of gastric neoplastic lesions, 
gastric cancer and type 1 gastric carcinoids: In a retrospective case-series 
(Lahner et al, 2015) the occurrence of gastric cancer in patients with type 1 
gastric carcinoids was described in 23% (4 out of 17) of patients with type 1 
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gastric carcinoids over a median follow-up period of 6 years. Three cases were 
intestinal-type adenocarcinomas and one a signet-ring cells diffuse gastric 
cancer, localized in 3 cases in the antrum. Thus, it seems to be worthwhile to 
monitor type 1 gastric carcinoids patients by a long-term surveillance 
programme, including an accurate bioptic sampling of antral mucosa. The 
effects of long-standing hypergastrinemia may be a possible explanation why 
patients with type 1 gastric carcinoids might develop more frequently gastric 
cancer. Hypergastrinemia has been proposed in many models of gastric 
carcinogenesis and seems to be a common causative factor in otherwise 
different circumstances; in all species where long-term hypergastrinemia has 
been induced, an increased risk of gastric malignancy, with adenocarcinoma 
phenotype and even the signet-ring cells phenotype, was observed (Waldum et 
al, 2014; Fossmark et al, 2008). Moreover, the long-term conservative 
management of type 1 gastric carcinoids exposes these patients to a higher risk 
of gastric cancer. This risk is basically present in atrophic gastritis, due to the 
pathophysiological changes related to gastric body atrophy, such as increased 
pH, reduced ascorbic acid and scavenging of nitrites and other potential 
carcinogenic substances (Fossmark et al, 2008). 
It has become apparent that besides H. pylori, other bacteria may be involved in 
gastric carcinogenesis; it has been shown that the gastric cancer microbiota was 
dominated by species of the genera Streptococcus, Lactobacillus, Veiollonella and 
Prevotella, albeit the roles of these species in the development of gastric cancer 
needs to be determined (Walker et al, 2014).  
Although the gastric cancer incidence has declined over the past decades, 
especially in Western countries, the mortality rate due to gastric cancer remains 
high (Ferlay et al, 2013). Detection and surveillance of patients with 
premalignant conditions, as atrophic gastritis and intestinal metaplasia, could 
potentially lead to detection and treatment of advanced lesions – i.e dysplastic 
lesions and gastric cancer – in an early stage (de Vries et al, 2008; Gonzalez et al, 
2010; den Hoed et al, 2013). In patients with premalignant conditions, the risk of 
developing gastric cancer may be further stratified by the location, severity, and 
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extent of gastric atrophy and/or metaplasia (El-Zimaity, 2006; Leung et al, 
2004). 
Several histological classifications have been developed for atrophic gastritis 
and preneoplastic changes. To date, in clinical practice and in research, the 
updated Sydney System is mainly used. This system combines topographic, 
morphological, and etiological information to standardize histological reporting 
(Dixon et al, 1996). More recently, the systems known as OLGA (operative link 
for gastritis assessment), and OLGIM (operative link on gastric intestinal 
metaplasia) assessment have been proposed for staging of gastritis (Rugge & 
Genta, 2005). Unfortunately, classifications are still difficult to use in clinical 
practice, and often present the disadvantage of important inter- and intra-
observer variation. (Rugge et al, 2011). 
As mandatory conditions to correctly adopt premalignant gastric lesions as 
reliable indicators for gastric cancer development, a standardized biopsy 
sampling protocol and an uniform, reproducible histological grading system 
need to be applied in clinical practice (Dinis-Ribeiro et al, 2012). A recent 
nationwide survey investigated in a community-based endoscopic setting what 
really happens in clinical practice with regard to the detection of gastric atrophy 
and intestinal metaplasia in dyspeptic patients (Lahner et al, 2014). In detail, a 
nationwide survey was conducted on 979 consecutive patients (50–65 years old) 
with dyspeptic symptoms, who were examined at24 gastrointestinal endoscopy 
units throughout Italy. Clinical information was collected from questionnaires; 
a standard bioptic mapping was performed in each unit, biopsies from each 
patient were analyzed by histopathology performed according to daily clinical 
practice in each local pathology centre. The results showed that separate 
descriptions of antral and corporal biopsies were included in 679 pathology 
reports (69%), whereas the standardized Sydney system was applied in 324 
reports (33%). Gastric atrophy without intestinal metaplasia and gastric atrophy 
with intestinal metaplasia were detected in 322 (33%) patients. The full 
adherence to Sydney system significantly increased the probability of detecting 
gastric atrophy with intestinal metaplasia (OR 9.6, 95% CI 5.5-16.7), gastric 
atrophy without intestinal metaplasia (OR 1.92, 95% CI 1.07-3.44), and either of 
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the conditions (OR 6.67, 95% CI 4.36-10.19). Thus, according to these findings, in 
daily routine practice only one third of histology reports were worked out 
adhering to Sydney system showing that international guidelines are poorly 
observed in clinical practice (Lahner et al, 2014). This may represent a critical 
element for surveillance strategies for gastric cancer. 
 
Pernicious anemia and risk of extra-gastric and non-gastrointestinal 
neoplasms 
In addition to gastric cancer and type 1 gastric carcinoid, pernicious anemia 
may also be associated with an increased risk of other cancers (Table 1). The 
role for immune dysregulation in hematological malignancies is well 
established; however, little is known about immune-related diseases, such as 
pernicious anemia, and the risk of hematological malignancies. Several works 
investigated for a possible association between pernicious anemia and 
hematological malignancies. Overall, pernicious anemia seemed to increase the 
risk for multiple myeloma (Brown et al, 2008; Anderson et al, 2009a; Murphy et 
al, 2015), acute myeloid leukemia and myelodisplastic syndrome (Anderson, 
2009b; Murphy et al, 2015). Conversely, the association between pernicious 
anemia and multiple myeloma was not confirmed by Lewis et al and Lindqvist 
et al. The study from Soderberg et al did not find any association between 
pernicious anemia and all hematological diseases, as well. 
Hypergastrinemia has been identified in patients with pernicious anemia as a 
physiologic response to the damage to the oxyntic mucosa and achlorhydria. 
However, beyond the role of gastrin in gastric acid secretion, it was also shown 
to stimulate the growth of epithelial cells and prevent apoptosis (Boursi et al, 
2016). Gastrin and its precursors activate several pathways important in 
tumorigenesis such as the beta catenin, MAP kinase and JAK2/STAT3 
pathways and were described in association with colorectal, pancreatic and 
liver cancers, other than gastric cancers and carcinoids (Talley et al, 1989; Borch 
et al, 1988; Karlson et al, 2000). Recently, Murphy et al found that individuals 
with pernicious anemia seem to be at increased risk for tonsilar cancer, 
hypopharyngeal cancer, esophageal squamous cell carcinoma, small intestinal 
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cancer and liver cancer. Both studies from Murphy et al and Boursi et al found 
no association between pernicious anemia and colorectal cancer risk.  
Previous studies have lacked the large number of cancer cases necessary to 
precisely estimate the magnitude of the association of pernicious anemia with 
other type of cancers. This paucity of prior studies has resulted in conflicting 
evidences and in the lack of any guidelines of clinical management for patients 
with pernicious anemia. 
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AIM OF THE STUDY 
 
Therefore, the aim of the present study was to systematically review the 
available literature on PA and the development of gastrointestinal cancers other 
than gastric cancers (GI-other than GC) and non-gastrointestinal cancers (non-
GIC) to estimate their incidence-rates. 
 
 
METHODS AND MATERIALS 
 
Literature search strategy  
The search was conducted according to PRISMA guidelines (Moher et al, 2009). 
The electronic database PubMed MEDLINE (U.S. National Library of Medicine, 
Bethesda, MD) was systematically searched combining as main keywords 
“pernicious anemia”, “autoimmune gastritis”, “cancer”.  
The search was translated into the following query: ("pernicious anaemia"[All 
Fields] OR "anemia, pernicious"[MeSH Terms] OR ("anemia"[All Fields] AND 
"pernicious"[All Fields]) OR "pernicious anemia"[All Fields] OR 
("pernicious"[All Fields] AND "anemia"[All Fields])) OR (autoimmune[All 
Fields] AND ("gastritis"[MeSH Terms] OR "gastritis"[All Fields])) AND 
("neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields]) 
AND ("humans"[MeSH Terms] AND (English[lang] OR French[lang] OR 
German[lang] OR Spanish[lang])). 
No publication date restrictions were imposed. Only reports published in 
English, German, French, Italian, and Spanish language were considered.  
 
Study selection 
Studies published up to April 27th 2017 were included in the systematic review 
if they fulfilled all of the following criteria: 1) observational study including 
patients with PA and reporting the numbers of non-gastric and non-GI cancers 
identified during a defined follow-up period; 2) the study was performed in 
adult patients; 3) the study was an original full paper which presented unique 
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data. Studies were excluded if 1) they were reviews, letters, editorials, case-
reports; 2) follow-up data were not available. 
Potentially relevant articles were screened for eligibility independently in an 
unblinded standardized manner by the two reviewers (MC, EL), initially by 
abstract and then by full text when necessary to determine whether they met 
the inclusion criteria. Disagreement between reviewers was resolved by 
discussion. The reference lists of the identified articles as well as of identified 
relevant reviews were manually searched for additional studies that may have 
been missed using the computer-assisted search strategy.    
 
Data Extraction  
Two reviewers (MC, EL) independently extracted the following information 
from each publication: the first author’s last name, year of publication, country 
of study location, study design, criteria for diagnosis of PA, sources of selection 
of participants, numbers of patients investigated, duration of follow-up period 
(years), calculation of person-years, age of patients (median or mean or range), 
gender, methods for identification of cancer, type of cancers, numbers of cancer 
cases.  
 
Outcome 
The outcome measure of interest was the incidence-rate of GI-other than GCs 
and non-GICs, which were calculated as the ratio between numbers of new 
cancer cases identified during the follow-up period and PA patients. 
 
Statistical analysis 
We extracted from each included study the number of incident non-GC and 
non-GIC cases and the number of PA patients exposed to risk. The cumulative 
incidence and the person-years (PY) incidence-rates in PA patients were 
calculated by the reviewers if not explicitly stated. 
The cumulative incidence was calculated as ratio between new non-GC and 
non-GIC cases and the number of PA patients. The PY incidence rates were 
calculated as the ratio between new non-GC and non-GIC cases and person-
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years. The pooled PY incidence rates of non-GC and non-GIC cases per organ or 
systems were calculated as the ratio between sum of new cases and the sum of 
PY. These incidence rates were then used and compared by meta-analysis with 
the annual cancer incidence rates of both genders in the general population 
aged over 40 years as reported for the single European countries by the website 
GLOBOCAN (GLOBOCAN, 2012). The weighted summary proportion (pooled 
proportion) under the fixed and random effects model were calculated by 
Freeman-Tukey transformation. In case of a positive "Heterogeneity test" (p-
value <0.05) the more appropriate random effects model was taken into 
consideration in which both the random variation within the studies and the 
variation between the different studies is incorporated (DerSimonian et al, 
1986). The extent of heterogeneity was investigated by Cochran’s Q and I² 
statistic. Q is the weighted sum of squares on a standardized scale, with low p-
values indicating presence of heterogeneity. I2 is the percentage of observed 
total variation across studies that is due to real heterogeneity rather than 
chance, calculated as I2 = 100%×(Q - df)/Q (where Q is Cochran's heterogeneity 
statistic and df the degrees of freedom. I2 lies between 0% and 100%, a value of 
0% indicates no observed heterogeneity, larger values show increasing 
heterogeneity (Higgins et al, 2003).  
The statistical analysis was carried out using a dedicated software package 
(MedCalc Software, Mariakerke, Belgium, version 12.7.8.0). 
 
Quality Assessment 
The two reviewers evaluated the quality of all included studies using the 
Newcastle-Otawa quality assessment scale (Wells et al). This scale awards a 
maximum of five points to each study. The considered categories are 
randomization, blinding of outcome assessment, description of withdrawals 
and dropouts, description and appropriateness of randomization and blinding. 
A study can be awarded a maximum of one point for each category. 
Discrepancy in quality assessment was discussed and resolved by two 
reviewers. 
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RESULTS 
Search results 
The electronic search strategy identified a total of 1.150records from electronic 
database (Figure 2). These articles were screened on the basis of title and 
abstract and, after application of the inclusion and exclusion criteria, 97 articles 
were retrieved for full-paper evaluation. Of these 97 full-papers, 20 met 
eligibility criteria and were subjected to data extraction (Armbrecht et al, 1990; 
Arvanitakis et al, 1979; Blackburn et al, 1967; Borch et al, 1986, Brinton et al, 
1986; Chan et al, 2008; Demmlet et al, 1966; Elsborg et al, 1973; Fallah et al, 2014; 
Hemminki et al, 20112; Hoffman et al, 1970; Hsing et al 1993; Landgren et al, 
2011; Mellemkjaer et al, 1996; Mosbech et al, 1950; Shah et al, 20124; Siurala et al, 
1966; Talley et al, 1989; von Knorre et al, 1975; Ye et al, 2003). Manual searching 
of reference lists of potentially relevant papers and reviews added 4 articles.  
 
Quality Assessment 
Details of the quality assessment of included studies are given in Table 2. Of 
the twenty included studies, four (20.0%) (Borch, Demmler, Siurala, von 
Knorre) resulted of very low quality, five (25.0%) (Armbrecht, Arvanitakis, 
Chan, Elsborg, Hoffman) of low quality, six (30.0%) (Blackburn, Fallah, 
Hemminki, Mosbech, Talley, Ye) of medium qualities and five (25.0%) (Brinton, 
Hsing, Landgren, Mellemkjaer, Saha) of high quality according to the 
Newcastle-Ottawa quality assessment scale. 
 
Characteristics of Included Studies  
The characteristics of the included studies are summarized in Table 3. Female 
gender was prevalent in 9 studies with a range between 51.3% and 72.7%, 44.3% 
in 1 study, only male patients were investigated in 2 studies, while in the 
remaining studies gender was not reported. Patients had a median age of 71.4 
years, in all studies ranging from 56.4 (Mosbech) to 79.0 (Chan) years.  
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The majority of the 20 studies were European, in particular 9 (45.0%) were from 
Northern Europe (Denmark, Finland, Sweden) and 5 (25.0%) from other 
European countries (United Kingdom, Germany). Five studies (25.0%) were 
American and only one study (5.0%) was performed in Eastern Countries 
(China). The design was prospective in 10 (50%) studies. Diagnostic criteria for 
the diagnosis of PA were carefully described in 10 (50.0%) studies. In particular, 
clinical criteria assessed by blood tests (macrocytic anemia, low serum vitamin 
B12or iron levels, hypergastrinemia, low pepsinogen I levels), positive Schilling 
test, gastric pH or megaloblastic bone marrow were used in 9 studies 
(Armbrecht, Arvanitakis, Borch, Chan, Hoffman, Mosbech, Siurala, Talley, von 
Knorre); data were extracted on the basis of International Classification of 
Disease (ICD) in 7 studies (Brinton, Hemminki, Hsing, Landgren, Mellemkjaer, 
Shah, Ye) and using hospital records in one study (Fallah). Three studies 
(Blackburn, Demmler, Elsborg) included patients with PA without providing 
further details. Most of the studies included hospitalized patients for PA, that 
could be after followed-up as outpatients, and 3 studies included outpatients 
referred to hematological units for anemia or local healthcare providers (Shah, 
Siurala, Talley). In the Blackburn study, patients were recorded in the files of 
eight PA clinics, but it was not indicated whether the patients were hospitalized 
or not. 
Most of the studies retrieved the diagnosis of GI and non-GI cancers biopsies 
using ICD codes from National Registers, three from local computer-based files 
(Chan, Landgren, Talley), while 4 studies made use of clinical interview/death 
certificates (Blackburn, Mosbech, Siurala, von Knorre).  Three studies did not 
specified how cancer diagnoses were assessed (Demmler, Elsborg, Hoffman). 
Regarding cancer incidence, 4 studies reported only GI-other than GC cases 
(Shah, Talley, von Knorre, Ye) and 3 studies only non-GIC cases (Elsborg, 
Fallah, Siurala), while the remaining studies reported both of them. 
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Cancer incidence 
With regard to the cancer incidence in PA patients included in this analysis, we 
found that the cumulative incidence-rate was 2.4%, ranging from 0.2%(Ye) to 
15.8% (Arvanitakis), with 1,993 new cancer cases on a total PA population of 
82,257 patients (15,285,818.3 PY) (Table 3), corresponding to a cumulative 
incidence rate of 13.0(100,000-PY). In particular, cancer incidence rates ranged 
from 0.2% (Shah, Ye) to 9.2% (Hsing) in the 9 Northern European studies, from 
0.2% (Shah) to 8.3% (von Knorre) in the 5 studies of other European countries, 
from 5.1% to 15.8% in the 5 American studies and was 6.0% in the Chinese 
study. 
Overall, a total of 67,654 (9,392,404.8 PY) and 45,373 (6,825,006.7 PY) PA patients 
were studied, with 767 and 1,194new cancer cases in GI-other than GC and non-
GIC group, respectively. 
Looking at GI-other than gastric cancers, the incidence rate was 1.1% (8.2 
100,000-PY), ranging from 0.2% (Shah, Ye) to 8.0% (Borch) (Table 4). Looking at 
non-GI cancers, the incidence rate was 2.6% (17.5 100,000-PY), ranging from 
0.3% (Hemminki) to 13.2% (Arvanitakis) (Table 5). 
Heterogeneity between studies was statistically significant in both groups 
(p<0.0001), with Chi-square test=761.02 and degree of freedom=14 in the GI-
other than GC group and Chi-square test=1730,21 and degree of freedom=15 in 
the non-GIC group. A meta-analysis was performed as shown in Figure 3A and 
3B by considering random and fixed effects, respectively, given the significance 
level of heterogeneity. We found a pooled incidence rate per person-year for 
non-GCs and non-GICs of 0.27 (95%CI: 0.16-0.42] and 0.23 [95%CI: 0.22-0-25]. 
Analysing the cancer incidence per organ or system (Table 6) (Figure 4), we 
found that the highest incidence rates (100,000-PY) were observed for skin 
cancer (32.8 – driven by non melanoma cancer: 61.6) and prostatic cancer (31.9). 
A meta-analysis performed using the calculated annual cancer incidence rates 
per organ showed an overall relative risk for cancer in PA as 0.68 (95% CI: 0.48-
0.95). With regard to site-specific cancers, PA patients (RR: 95%CI) showed a 
lower RR as compared to the general population for lung (0.26: 0,21 to 0,31), 
thyroid (0.34: 0,21 to 0,57), esophagus (0.26: 0,178 to 0,371), colo-rectum (0.14: 
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0,098 to 0,19), liver (0.18: 0,13 to 0,24), pancreas (0.65: 0,45 to 0,93), breast (0.17: 
0,13 to 0,22), ovary (0.45: 0,30 to 0,67), prostate (0.72:0,623 to 0,84), kidney (0.61: 
0,43 to 0,86) and non-melanoma skin cancer (0.56: 0.50-0.61). In contrast, PA 
patients showed a higher risk than the general population for biliary tract 
cancer (1.81: 1,21 to 2,70) and for hematological malignancies as multiple 
myeloma (2.83: 1,76 to 4,55), Hodgkin lymphoma (3.0: 1,35 to 6,68), non 
Hodgkin lymphoma (2.08: 1,58 to 2,75), and leukemia (1.56: 1,16 to 2,12) (Figure 
5). 
 
 
DISCUSSION 
Evidence on overall cancer incidence in PA are quite sparse and conflicting. To 
our knowledge, this is the first systematic review on the estimate of GI-other 
than GCs and non-GICs incidence in these patients.  
From 1,154 articles retrieved from a search strategy with no time limit, we 
selected 20 papers according with our inclusion criteria, published between 
1950 and 2014 concerning a total of 82,257 PA patients (15,285,818.3 PY). 
Overall, 1,993 new cases of cancer other than gastric were identified, 
corresponding to an overall incidence rate of 2.4%, ranging from 0.2% to 15.8%. 
In detail, 767 and 1,194 new cases of GI cancers other than GC and non-GIC, 
respectively, were identified, with a crude incidence rate of 1.1% (8.2100,000-
PY) and 2.6% (15.7100,000-PY), respectively. Comparing with the general 
population, PA patients showed an overall lower relative risk (0.68) of 
developing cancer, even if we found an increased risk for haematological 
malignancies (in particular, multiple myeloma [2.83] and Hodgkin lymphoma 
[3.0]), and biliary tract cancers (1.8).  
Individuals with pernicious anemia have long been suggested to have increased 
risk of gastric cancer as well as gastric carcinoid tumors in a number of studies. 
Such an association is plausible, as a less acidic stomach (hypochlorhydria) as 
well as chronic inflammation are among the mechanisms by which H. pylori is 
thought to cause gastric cancer. In addition to gastric cancer, pernicious anemia 
has been reported to be associated with an increased risk of other cancers. 
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Anyways, the paucity of prior studies of PA and cancer leave this association 
still controversial.  
In our analysis, we found that PA patients showed a lower relative risk of GI-
other than GCs (esophagus, liver, pancreas and colorectum). The possible 
association between PA and GI-other than GCs has been quite debated in 
literature, though providing conflicting evidence. The inverse relationship 
between gastric atrophy and esophageal cancer has already been observed in a 
small number of studies (Cook et al, 2010; Islami et al, 2011; Kamangar et al, 
2009), which is thought to reflect reduced acid reflux from the stomach to the 
esophagus as a result of the loss of parietal cell. On the contrary, Murphy et al 
found a positive association with esophageal squamous cell carcinoma, but no 
association with esophageal adenocarcinoma. As the authors stated, this 
relationship is not fully understood and may, or may not, be causal (Murphy et 
al, 2015). Gastrin at physiological concentrations was shown to act as a growth 
factor for colorectal cancer both through endocrine as well autocrine/paracrine 
mechanisms and pre-malignant adenomas were also shown to express an 
isoform of the cholecystokinin B/gastrin receptor (Singh et al, 2000; Smith et al, 
2000). However, the lack of association between PA and colorectal cancer risk 
was recently demonstrated in the largest population study currently available 
(Boursi et al, 2016). Only a previous work showed an increased risk of liver 
cancer for people with PA (Hsing et al, 1993), even if it was recently confirmed 
only in women (Murphy et al, 2015). No specific association of PA with lung, 
breast, prostate and kidney cancer has been reported in a recent population-
based study (Murphy et al, 2015), supporting our results. Thus, the finding of 
the present systematic review keep in step with these data denying the higher 
risk of developing cancers in these organs in patients with PA. 
In our analysis, we found an increased relative risk for haematological 
malignancies and biliary tract cancers. The role for immune dysregulation in 
hematological malignancies is well established and several works investigated 
for a possible association between PA and hematological malignancies. Overall, 
PA seemed to increase the risk for multiple myeloma (Anderson et al, 2009a; 
Brown et al, 2008; Murphy et al, 2015), acute myeloid leukemia and 
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myelodisplastic syndrome (Murphy et al, 2015, Anderson et al2009b). 
Conversely, the association between pernicious anemia and multiple myeloma 
was not confirmed by Lewis et al and Lindqvist et al. The study from Soderberg 
et al did not find any association between PA and all hematological diseases, as 
well. 
The significant association between the risk of haematological malignancies 
could be related to vitamin B12 deficiency (Anderson et al, 2009a; Anderson et 
al, 2009b). Vitamin B12 deficiency could promote the development of cancer by 
causing derangement of one-carbon metabolism nutrients (folate, vitamin B6, 
riboflavin, homocysteine) associated to aberration in both DNA methylation 
and DNA synthesis, as proposed by several authors (Friso & Choi, 2005; 
Miranti et al, 2017). When insufficient B12 is available, cellular folates 
accumulate in the methylfolate form, but cannot be metabolically utilized due 
to the block in the methyonine synthase reaction, creating a functional folate 
deficiency commonly referred to as “methylfolate trap” (Herbert, 1994). 
Previous studies in bone marrow cells and immortalized cultured cells 
(Wickramasinghe & Fida, 1994; Wickramasinghe & Fida, 1993) demonstrated 
that B12 deficiency increased uracil misincorporation into DNA, suggesting that 
this functional folate deficiency by B12 deficiency results in inadequate 
thymidylate synthesis. Some authors observed that localized B12 deficiency in 
squamous-cell lung cancer tissue was associated with genomic DNA 
hypomethylation, suggesting that decreased availability of methylfolate by B12 
deficiency subsequently reduces genomic DNA methylation (Friso & Choi, 
2005). 
We also found a positive association of PA with the risk of biliary tract cancers. 
There are no specific literature data on this association, anyways, a possible role 
for DNA hypomethylation can be hypothesized, considering that aberrant DNA 
methylation is an epigenetic mechanisms that can occur early in carcinogenesis 
(Esteller et al, 2008). A very recent molecular study demonstrated the up-
regulation of Dicer in cholangiocarcinoma cells, promoting their proliferation 
and invasion (Cheng et al, 2017). Dicer is known to regulate methylation of CpG 
island in mammalian cancer cells (Ting et al, 2008, Chen et al, 2011), interacting 
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with heterocromatin protein 1α (HP1α).  DNA methylation has also become one 
of the key molecular mechanisms in the tumorigenesis of gallbladder (Tekcham 
et al, 2016). In a very recent study, the aberrant methylation of the WIF-1 
promoter was found to be involved in the malignant transformation of 
gallbladder cancer (Lin et al, 2017). Also, hypergastrinemia has been identified 
in PA patients as a physiologic response to the damage of the oxyntic mucosa 
and achlorhydria. However, beyond the role of gastrin in gastric acid secretion, 
it was also shown to stimulate the growth of epithelial cells and prevent 
apoptosis (Todisco et al, 2001; Seva et al, 1994; Ferrand et al, 2006; Maddalo et 
al, 2014). 
We are aware that this study has some limits. To evaluate the quality of 
included studies we applied the Newcastle-Ottawa Quality Scale for cohort 
studies, which permits a critical appraisal of data (Well et al). We found that 
almost half of the included studies had high/medium quality. In spite of this, 
clinical and methodological heterogeneity was present among the 20 studies 
included, resulting in a wide range for the observed overall cancer incidence 
rate (0.2%-15.8%). The different approach across the studies should take into 
account the decade in which the studies were performed. Diagnostic tools for 
both PA and cancer diagnosis have changed over time. A cancer diagnosis 
obtained from death certificates in the older studies could be not directly 
comparable with those obtained from ICD code in National Cancer Registers. 
Also, 6 six studies did not specifically report how cancer was detected. 
Moreover, we excluded from this analysis the incidence rate for gastric cancer. 
We know that the introduction of the fiberscope and, subsequently, of the video 
endoscope has been a revolution in the diagnosis of stomach diseases. This 
observation could impact the number of esophageal cancers reported in older 
studies: some of those cases could include primary misdiagnosed gastric cancer. 
Notwithstanding these limits, we performed a meta-analysis based on the 
calculated GI-other than gastric and non-GI cancer incidence rates in PA 
patients. A further limit of this systematic review is that for the comparison 
with the general population used for the calculations of the relative risk of 
cancer in PA data from cancer registries were used, but the retrieved study did 
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not report on controls and this was a way to get estimates on the association of 
the single cancers with PA. Though we are aware that the results of this meta-
analysis may be biased by the limits explained above, we think however that 
they should be acceptable as an estimate of the overall probability of PA 
patients to develop cancer and may represent a starting point to design further 
population-based prospective studies. Of note, this is the first systematic review 
performed on this topic. 
In conclusion, this systematic review showed an overall cancer risk for PA 
patients that do not appear to be increased in comparison to the general 
population, except for haematological malignancies and biliary tract cancers, 
except for haematological malignancies and biliary tract cancers. Further high 
quality studies are needed to confirm the risk of specific cancer development in 
PA patients, so as to provide clinical guidance for a careful follow-up of these 
patients.  
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Figure 1 – Diagnosis of pernicious anemia (Annibale et al, 2011). 
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Figure 2 – Flow-chart of study selection.  
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Figure 3 – Annual cancer incidence rates in PA patients of the selected 
studies. A) GI-other than gastric cancer incidence. p<0.0001, I2=98.16% (95%CI 
97.68-98.54); B) Non-GI cancer incidence. p<0.0001, I2=99.13% (95%CI 98.97-
99.27). 
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Figure 4 - Cancer incidence (PY per 100,000) per organ/system in PA patients. 
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Figure 5 – Cancer relative risk per organ in PA patients comparing with the general population. p<0.0001; I2=96.79%; 95% CI: 
95.92-97.47. 
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SEER-Medicare data 
13.486 77 
(50.9%) 
Myeloid 
malignancies 
Acute myeloid leukemia=177 (1.57) 
Chronic myeloid leukemia=21 (0.74) 
Myelodysplastic syndromes=148 
(2.38) 
Chronic myeloproliferative 
disorder=25 (1.11) 
 
Boursi, 2016 UK Nested case-
control study 
Read code Patients traced from THIN 
databse 
22.098 71.3 
(45%) 
Colorectal 
cancer 
154 (1.02) 
Brown, 2008 US Retrospective 
cohort study 
ICD code Patients traced from discharge 
records in US Veterans Affairs 
Hospitals 
4.641 59.9 (0%) Multiple 
myeloma 
(MM)/MGU
S 
MM= 27 (RR 2.15) 
MGUS= 14 (RR 1.97) 
Landgren, 2006 
 
 
Sweden, Denmark Retrospective 
population-
based study 
ICD code from 
Swedish 
Inpatient 
Register and 
Danish Inpatient 
and Outpatient 
Register 
Patients traced from the 
Swedish Family-Cancer 
Database and the Danish 
Cancer Register  and Danish 
Central Population Register 
7.764 54-76 (30-
35%) 
Chronic 
lymphocitic 
leukemia 
(CLL) 
CLL=31 (1.94) 
Lewis, 1994 
 
 
US Population-
based, case-
control study 
Personal 
interviews 
Patients traced from 3 US 
Population-based cancer 
registries 
573 62.3-65.3 
(47.4-
55.8%) 
Multiple 
myeloma 
(MM) 
MM=11 (1.1) 
Lindqvist, 2011 
 
 
Sweden Retrospective, 
population 
case-control 
study 
Discharge 
diagnosis from 
Swedish 
Inpatient 
Register 
Patients raced from Swedish 
Cancer Register and Swedish 
Inpatient Register  
7.314 71 (45-
50%)  
Multiple 
myeloma 
(MM)/MGU
S 
MM=48 (1.2)  
MGUS=19 (1.8) 
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Table 1 - Pernicious anemia in cancer patients. PA: pernicious anemia; ns: not specified. 
Murphy, 2015 
 
 
 
US Population- 
based, case-
control study 
Medicare claims 
data 
Patients traced from SEER 
database-Medicare 
1.138.390 65->85 
(47%) 
All type of 
cancer 
Tonsil (2.00) 
Hypopharinx (1.92) 
Small bowel (1.63) 
Liver (1.49) 
Myeloma (1.55) 
Acute myeloid leukemia (1.68) 
Myelodysplastic syndrome (2.87) 
Soderberg, 2006 
 
 
Sweden Case-control 
study 
Swedish 
Hospital 
Discharge 
Registry 
Patients traced from the 
Swedish Hospital Discharge 
Registry and the Swedish 
Cancer Registry 
ns ns Hematologic
al 
malignancies 
Chronic Lymphoid Leukemia 
(CLL)=8 (0.7) 
Acute Myeloid Luekemia=7 (1.1) 
CML=1 (0.6) 
Leukemia (exlc. CLL)=14 (1.3) 
Non Hodking Lymphoma=29 (0.8) 
Myeloma=14 (0.8) 
All hematological malignancies=66 
(0.9) 
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Table 2 – Quality Assessment of included studiesaccording to the Newcastle-Otawa quality assessment scale. HQ= high quality 
(nine stars); MQ=medium quality (seven or eight stars); LQ=low quality (five or six stars); VLQ=very low quality (four stars or 
less). 
 
Author Year 
 
Selection Comparability Outcome assessment Global Quality 
Assessment 
 
 1 2 3 4 1 2 1 2 3   
Armbrecht 1990  *	 	 *	 *	 	 	 *	 *	 *	 LQ  
Arvanitakis  1979  	 *	 *	 	 *	 	 *	 *	 	 LQ  
Blackburn  1967  *	 *	 *	 	 *	 *	 *	 	 *	 MQ  
Borch  1986  *	 	 *	 *	 	 	 *	 *	 *	 VLQ  
Brinton  1989 *	 *	 *	 *	 *	 *	 *	 *	 *	 HQ  
Chan  2008  *	 	 *	 	 	 	 *	 *	 *	 LQ  
Demmler 1966  *	 	 *	 	 	 	 *	 *	 	 VLQ  
Elsborg 1973  *	 	 *	 	 	 	 *	 *	 *	 LQ  
Fallah 2014 *  *	 *   *	 	 *  *  *  MQ  
Hemminki 2012 *  *	 *   *	 	 *  *  *  MQ  
Hoffman  1970  *	 	 *	 *	 	 	 *	 *	 *	 LQ  
Hsing 1993  *	 *	 *	 *	 *	 *	 *	 *	 *	 HQ  
Landgren  2011  *	 *	 *	 *	 *	 *	 *	 *	 *	 HQ  
Mellemkjaer 1996  *	 *	 *	 *	 *	 *	 *	 *	 *	 HQ  
Mosbech  1950  *	 *	 *	 	 *	 *	 *	 *	 *	 MQ  
Shah 2014 *	 *	 *	 *	 *	 *	 *	 *	 *	 HQ  
Siurala 1966 	 *	 	 	 	 	 *	 	 *	 VLQ  
Talley 1989 	 *	 *	 *	 *	 *	 *	 *	 	 MQ  
Von Knorre  1975  *	 	 *	 	 	 	 *	 *	 	 VLQ  
Ye 2003 
 
*	 *	 *	 *	 *	 *	 *	 *	 	 MQ  
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Author 
 
Country Study Design  PA 
Diagnosis 
Patients 
(inpatients, 
outpatients, 
general 
population) 
 
Populatio
n 
(n) 
Age, yrs 
Median 
or Mean 
or Range 
(Female, 
%) 
 
Follow-
up, years 
(person-
years) 
Diagnostic Tool 
for 
Identification 
of  cancer 
Cases of 
GI-other 
than GC, 
n 
(incidence
, %) 
Cases of 
non-GIC, 
n 
(incidence
, %) 
Overall 
cases of 
cancers 
other than 
gastric, n 
(incidence, 
%) 
Armbrecht, 1990  
 
 
Germany Prospective, 
follow-up 
study 
BT 
BM 
Patients traced 
from 
departments of 
Medicine, 
Haematology, 
Gastroenterolog
y in London 
73 63 (20-79)  
44.3 % 
6,4 (467,2) ns (symptoms 
monitoring 
during clinical 
follow-up)  
1 (1.4%) 1 (1.4%) 2 (2.7) 
Arvanitakis, 
1979  
 
USA Prospective BT 
ST 
BM 
Ach  
 
ns 38 69.4 (44-
88) 
51.3% 
6.9 (1-43) 
(262.2) 
ns (symptoms 
monitoring 
during clinical 
follow-up)  
1 (2.6%) 
 
5 (13.1%) 6 (15.8) 
Blackburn, 1967  
 
 
United 
Kingdo
m  
Prospective   nr Patients 
recorded in the 
files of eight PA 
clinics  
1625 nr 3 (4,875) Death 
certificates  
 
 44 (2.7%) 10 (0.6%) 54 (3.3) 
Borch, 1988  
 
Sweden Prospective BT 
ST 
Patients from 
two healthcare 
districts 
361 73 
(66.2%) 
 
7 (2,527)  National Cancer 
Register and 
Regional 
Oncologic 
Center records - 
histologically 
verified 
14 (3.9%) 15 (4.1%) 29 (8.0) 
Brinton, 1989  
 
USA Retrospective 
cohort-
analysis 
ICD on 
computer-
based file 
Patients 
hospitalized at  
Veterans 
Administration 
Hospitals, across 
USA 
5161 72.8 
0% 
6.8 
(35,094.8) 
ICD on 
computer-based 
file  
62 (1.2%) 375 
(7.3%) 
 
437 (8.5) 
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Chan, 2008  
 
 
China Hospital-
based, 
longitudinal 
prospective 
study 
BT  
BM 
 
 
Patients 
hospitalized at  
single hospital 
in Hong Kong 
367 79 (57-93) 
nr 
 
≈4 
(≈1,468) 
 
Electronic 
patient-record 
system 
7 (1.9%) 
 
15 (4.0%) 
 
22 (6.0) 
Demmler, 1966 
 
Germany Retrospective  
 
nr  Patients 
hospitalized in 
35 German 
Hospitals 
238 nr maximum 
35 years 
(≈8,330) 
ns 6 (2.5%) 
 
14 (5.9%) 20 (8.4) 
Elsborg, 1973  
 
Denmark Prospective nr Patients 
hospitalized for 
PA and 
followed-up as 
outpatients 
82  68 (33-86) 
61% 
9 (0.5-
31)* (738) 
 
ns 0 2 (2.4%)  2 (2.4) 
Fallah, 2014 
 
Sweden Retrospective 
cohort study 
Hospital 
discharges
, 
Outpatient
s 
registries, 
Primary 
Health 
Care 
registries 
Patients traced 
from Swedish 
healthcare 
databases 
12.651 nr 9.4 
(118,919.4
) 
Records from 
Swedish Cancer 
Registry and 
cause-specific 
death registry 
- 45 (0.3%) 
 
45 (0.3) 
 
Hemminki, 2012 
 
Sweden Follow-up 
study 
ICD code 
at 
hospitaliza
tion 
Patients traced 
from the 
Swedish 
Hospital 
Discharge 
Register 
(hospitalized 
PA) and 
Swedish Cancer 
Registry 
11.839 ns 5.8 
(68,666.2) 
Records from 
Swedish Cancer 
Registry  
145 
(1.2%) 
34 (0.3%) 
 
179 (1.5) 
Hoffman, 1970  
 
USA Prospective BT  
ST 
 
Patients  
hospitalized for 
PA and 
followed-up as 
outpatients 
138  74 (33-87) 
nr 
≈11 
(≈1,518) 
ns 1 (0.7%) 
 
6 (4.3%) 7 (5.1) 
Hsing, 1993 
 
 
Sweden Prospective 
 
ICD on 
computer-
based file 
Patients 
hospitalized for 
PA in the 
Uppsala health 
4517 73.1 
55.3% 
5.9 
(26,650.2) 
Records from 
the Swedish 
Cancer Registry 
in linkage with 
142 
(3.1%) 
 
 
275 
(6.1%) 
417 (9.2) 
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Table 3 
- 
Charact
care region that 
includes 6 
countries in 
Sweden 
the Swedish 
National Death 
Register 
Landgren, 2011   
 
USA Retrospective 
population-
based study 
ICD on 
computer-
based file 
Patients 
hospitalized at 
Veterans 
Administration 
Hospitals, across 
USA 
2810 57.67 
0% 
≈12.02 
(≈33,776.2
) 
ICD code from 
discharge 
diagnosis 
175 
(6.2%) 
85 (3.0%) 
 
260 (9.2) 
Mellemkjaer, 
1996  
 
Denmark Retrospective  ICD on 
computer-
based file 
Patients traced 
from nationwide 
Hospital 
Discharge 
Register in 
Denmark 
5072 71 for 
male; 73 
for female; 
66% 
5.1 (1-15) 
(25,767.2) 
ICD code from 
Danish Cancer 
Registry 
107 
(2.1%) 
 
 
295 
(5.8%) 
 
402 (7.9) 
Mosbech, 1950  
 
 
Denmark Retrospective BT  
Ach 
Patients  
hospitalized for 
PA and 
followed-up as 
outpatients 
301 56.4 for 
male; 59.1 
for female; 
72.7% 
10.3 for 
male,  
10.7 for 
female 
(10.6) 
(3,190.6) 
Death 
certificates 
2 (0.7%) 
 
4 (1.3%) 6 (2.0) 
Shah, 2014 
 
 
UK Retrospective THIN 
Read 
diagnostic 
code 
Patients traced 
in The Health 
Improvement 
Network 
(THIN) database 
15.324 68.79 - 
69% 
4.31 
(66,046.44
)  
THIN Read 
diagnostic code 
30 (0.2%) - 30 (0.2) 
Siurala, 1966 
 
Finland Prospective BT  
Ach 
ST 
Outpatients 
referred to 
Hematological 
Department 
100 ns 10-15 
(1,250) 
Follow-up 
interview on 
death causes 
0 4 (4%) 4 (4) 
Talley, 1989 
 
 
 
 
USA Retrospective 
population-
based cohort 
study 
BT 
BM 
ST 
Ach 
Patients traced 
from the 
Rochester 
Epidemiology 
Project database 
150 70 (63%) 10.9 
(1,635) 
Outpatient and 
Inpatient  
records of local 
Medicare 
providers 
9 (6%) - 9 (6) 
Von Knorre, 
1975  
 
Germany Retrospective BT 
BM 
Ach 
Patients 
hospitalized for 
PA and 
followed-up as 
outpatients 
145 nr 13.1 (2-
35) 
(1,899.5) 
Death 
Certificates  
12 (8.3%) - 12 (8.3) 
Ye, 2003 
 
 
Sweden Retrospective 
register-based 
cohort study 
ICD code 
in Swedish 
Inpatient 
Register 
Patients traced 
from Swedish 
Inpatient 
Register linked 
to the Swedish 
Cancer Register 
21.265 74.3 
(60.3%) 
7.1 
(150,981.5
) 
ICD code from 
the Swedish 
Cancer Register 
50 (0.2%) - 50 (0.2) 
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eristics of the included studies. PA: pernicious anemia; ns: not specified; nr: not reported; *duration from the time of PA 
diagnosi
s; ST: 
Schilling 
test; BT: 
Blood 
test; BM: 
bone 
marrow; 
Ach: 
achloryd
ria; EGD: 
gastrosco
py. 
 
 
 
 
 
 
 
 
 
 
Author 
 
Country Study Design PA 
Diagnosis 
 
Patients 
(inpatients, outpatients, 
general population) 
 
Population 
(n) 
Age, yrs 
Median or 
Mean 
or Range 
(Female, %) 
 
Follow-up, 
years 
(person-
years) 
Cases of GI-other than 
GC, n (cumulative 
incidence, %) 
[incidence rate PY, %] 
Armbrecht, 1990  
 
Germany Prospective, 
follow-up study 
BT 
BM 
Patients traced from 
departments of 
73 63 (20-79)  
44.3  
6,4 (467.2) All=1 (1.4) [0.2] 
Colon=1  
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 Medicine, Haematology, 
Gastroenterology in 
London 
Arvanitakis, 1979  
 
USA Prospective BT 
ST 
BM 
Ach  
 
ns 38 69.4 (44-88) 
51.3 
6.9 (1-43) 
(262.2) 
All=1 (2.6) [0.4] 
Rectum=1 
 
Borch, 1988  
 
Sweden Prospective BT 
ST 
Patients from two 
healthcare districts 
361 73 (66.2) 
 
7 (2,527)  All=29 (8.0) [1.1] 
Colon=4 
Rectum=1 
Liver=1 
Biliary tract=1 
Pancreas=5 
§Other digestive=17 
Brinton, 1989  
 
USA Retrospective 
cohort-analysis 
ICD on 
computer-
based file 
Patients hospitalized at  
Veterans Administration 
Hospitals, across USA 
5161 72.8 
0 
6.8 (35,095) All=62 (1.2) [0.2] 
Esophagus=11 
Small bowel=1 
Colon=34  
Rectum=1 
Liver=2 
Biliary tract=4 
Pancreas=7 
§Other digestive=2 
Chan, 2008  
 
 
China Hospital-based, 
longitudinal 
prospective study 
BT  
BM 
Neu  
 
Patients hospitalized at  
single hospital in Hong 
Kong 
367 79 (57-93) nr 
 
≈4 (≈1,468) 
 
All =7 (1.9) [0.5] 
Small bowel=1 
Colon=4 
Liver=1 
Biliary tract=1 
 
Demmler, 1966 
 
Germany Retrospective  
 
nr  Patients hospitalized in 
35 German Hospitals 
238 nr maximum 35 
years 
(≈8,330) 
All=6 (2.5) [0.07] 
Esophagus=1 
Small bowel=1 
Rectum=1 
Pancreas=3 
 
Hemminki, 2012 
 
Sweden Follow-up study ICD code at 
hospitalizati
on 
Patients traced from the 
Swedish Hospital 
Discharge Register 
(hospitalized PA) and 
Swedish Cancer Registry 
11.839 ns 5.8 
(68,666.2) 
All=145 (1.2) [0.2] 
Esophagus=26 
Small bowel=9 
Colon=72 
Rectum=35 
Anus=3 
Hoffman, 1970  
 
USA Prospective BT  
ST 
 
Patients  hospitalized for 
PA and followed-up as 
outpatients 
138  74 (33-87) nr ≈11 (≈1,518) All=1 (0.7) [0.07] 
Colon=1 
 
Hsing, 1993 Sweden Prospective ICD on Patients hospitalized for 4517 73.1 5.9 All=142 (3.1) [0.5] 
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 computer-
based file 
PA in the Uppsala health 
care region that includes 
6 countries in Sweden 
55.3 (26,650.3) Esophagus=15 
Colon=36 
Rectum=25 
Liver=14 
Biliary tract=18 
Pancreas=34 
 
 
Landgren, 2011   
 
USA Retrospective 
population-based 
study 
ICD on 
computer-
based file 
Patients hospitalized at 
Veterans Administration 
Hospitals, across USA 
2810 57.67 
0 
≈12.02 
(≈33,776.2) 
All=175 (6.2) [0.5] 
Esophagus=30 
Small bowel=5 
Colon=59 
Rectum=38 
Liver=18 
Pancreas=25 
Mellemkjaer, 1996  
 
Denmark Retrospective  ICD on 
computer-
based file 
Patients traced from 
nationwide Hospital 
Discharge Register in 
Denmark 
5072 71 for male; 73 
for female; 
66 
5.1 (1-15) 
(25,768.2) 
All=107 (2.1) [0.4] 
Esophagus=8 
Small bowel=2 
Colon=50 
Rectum=19 
Liver=3 
Biliary tract=6 
Pancreas=19 
 
 
Mosbech, 1950  
 
 
Denmark retrospective BT  
Ach 
Patients  hospitalized for 
PA and followed-up as 
outpatients 
301 56.4 for male; 
59.1 for female; 
72.7 
10.3 for male 
10.7 for 
female 
(10.69 
(3190.6) 
All=2 (0.7) [0.06] 
Colon=1 
Liver=1 
 
 
Shah, 2014 
 
 
UK Retrospective THIN Read 
diagnostic 
code 
Patients traced in The 
Health Improvement 
Network 
(THIN) database 
15.324 68.79 - 69 4.31 
(66,046.44)  
All=30 (0.2) [0.04] 
Pancreas=30 
Talley, 1989 
 
 
 
 
US Retrospective 
population-based 
cohort study 
BT 
BM 
ST 
Ach 
Patients traced from the 
Rochester Epidemiology 
Project database 
150 70 (63) 10.9 (1,635) All=9 (6.0) [0.6] 
Colon=9 
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Ye, 2003 
 
 
 Retrospective 
register-based 
cohort study 
ICD code in 
Swedish 
Inpatient 
Register 
Patients traced from 
Swedish Inpatient 
Register linked to the 
Swedish Cancer Register 
21.265 74.3 (60.3) 7.1 
(150,981.5) 
All=50 (0.2) [0.03] 
Esophagus=50 
OVERALL 
 
 
    67.654  138.83 
(9,392,404.8
2) 
ALL=767 (1.1) [0.008] 
 58 
Table 4 - Characteristics of the included studies reporting GI-other than gastric cancer cases. PA: pernicious anemia; ns: not 
specified; na: not applicable; nr: not reported; *duration from the time of PA diagnosis; §Cancer type not specified; ST: Schilling 
test; BT: Blood test; BM: bone marrow; Ach: achlorhydria; EGD: gastroscopy. 34 and 12 cancer cases reported from Blackburn 
(1967) and van Knorre (1975), respectively, were excluded because it was not specified if GI or extra-GI cases.   
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Author 
 
Country Study Design PA 
Diagnosis 
 
Patients 
(inpatients, 
outpatients, general 
population) 
 
Population 
(n) 
Age, yrs 
Median or 
Mean 
or Range 
(Female, %) 
 
Follow-up, 
years 
(person-
years) 
Cases of non-GIC, n 
(cumulative incidence, %) 
[incidence rate PY, %] 
Armbrecht, 1990  
 
 
Germany Prospective, 
follow-up study 
BT 
BM 
Patients traced from 
departments of 
Medicine, 
Haematology, 
Gastroenterology in 
London 
73 63 (20-79)  
44.3  
6,4 (467.2) All=1 (1.4) [0.2] 
Thyroid=1 
Arvanitakis, 1979  
 
USA Prospective BT 
ST 
BM 
Ach  
 
ns 38 69.4 (44-88) 
51.3 
6.9 (1-43) 
(262.2) 
All=5 (13.2) [1.9] 
CNS (Meningioma)=1 
Sinus maxillary=1 
Larynx=1  
Thyroid=1   
Kidney and lymphoma and 
acoustic neuroma=1 
Blackburn, 1967  
 
 
United 
Kingdom  
Prospective   nr Patients recorded in the 
files of eight PA clinics  
1625 nr 3 (4,875) All=10 (0.6) [0.2] 
Leukemia=9 
Lymphosarcoma=1 
Borch, 1988  
 
Sweden Prospective BT 
ST 
Patients from two 
healthcare districts 
361 73 (66.2) 
 
7 (2,527)  All=24§ (6.6) [0.9] 
Brinton, 1989  
 
USA Retrospective 
cohort-analysis 
ICD on 
computer-
based file 
Patients hospitalized at  
Veterans 
Administration 
Hospitals, across USA 
5161 72.8 
0 
6.8 
(35,094.8) 
All=375 (7.3) [1.1] 
CNS=6 
Eye=1 
Thyroid=1 
Buccal cavity and pharynx=50 
Lung= 80 
Other respiratory=13 
Bone=6 
Connective/soft tissue=5 
Melanoma=12 
Breast=1 
Prostate=90 
Other genital=3 
Bladder=24 
Kidney and other urinary=10 
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Hodgkin Lymphoma=1 
Other lymphoid tissue=6 
Multiple myeloma=9 
Lymphatic leukemia=4 
Myeloid leukemia=17 
Other leukemia=10 
Other=26§ 
 
Chan, 2008  
 
 
China Hospital-based, 
longitudinal 
prospective 
study 
BT  
BM 
Neu  
 
Patients hospitalized at  
single hospital in Hong 
Kong 
367 79 (57-93) nr 
 
≈4 (≈1,468) 
 
All=15 (4.1) [1.0] 
CNS (meningioma)=1 
Hypopharynx=1 
Lung=7 
Soft tissue (head and neck)=1 
Thymoma=1 
Breast=1 
Cervix uteri=1 
Corpus uteri=1 
Myelodisplastic syndrome=1  
Demmler, 1966 
 
Germany Retrospective  
 
nr  Patients hospitalized in 
35 German Hospitals 
238 nr maximum 
35 years 
(≈8,330) 
All=14 (5.9) [0.2] 
Sinus maxillary=1 
Lower lip=1 
Lung=5 
Breast=1 
Ovarian=1 
Cervix uteri=1 
Kidney=1 
Bladder=1 
Connective (sarcoma)=1 
Metastasis (unknown 
primary)=1 
Elsborg, 1973  
 
Denmark Prospective nr Patients hospitalized 
for PA and followed-
up as outpatients 
82  68 (33-86) 
61 
9 (0.5-31)* 
(738) 
 
All=2 (2.4) [0.3] 
Lung=1 
Acute leukemia=1  
Fallah, 2014 
 
Sweden Retrospective 
cohort study 
Hospital 
discharges, 
Outpatients 
registries, 
Primary 
Health 
Care 
registries 
Patients traced from 
Swedish healthcare 
databases 
12.651 nr 9.4 
(118,919.4) 
All=45 (0.4) [0.04] 
Non Hodgkin lymphoma=45  
Hemminki, 2012 
 
Sweden Follow-up study ICD code 
at 
hospitalizat
ion 
Patients traced from 
the Swedish Hospital 
Discharge Register 
(hospitalized PA) and 
Swedish Cancer 
Registry 
11.839 ns 5.8 
(68,666.2) 
All=34 (0.3) [0.05] 
Upper digestive tract 
(pharynx)=34 
 
Hoffman, 1970  
 
USA Prospective BT  
ST 
Patients  hospitalized 
for PA and followed-
138  74 (33-87) nr ≈11 
(≈1,518) 
All=6 (4.3) [0.4] 
Prostate=3 
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 up as outpatients Multiple myeloma=1 
Hematologicsl malignancies=2 
 
Hsing, 1993 
 
 
Sweden Prospective 
 
ICD on 
computer-
based file 
Patients hospitalized 
for PA in the Uppsala 
health care region that 
includes 6 countries in 
Sweden 
4517 73.1 
55.3 
5.9 
(26,650.2) 
All=275 (6.1) [1.0] 
CNS=10 
Buccal cavity=16 
Larynx=1 
Lung=25 
Prostate=58 
Breast=36 
Cervix uteri=6 
Corpus uteri=10 
Ovary=9 
Kidney=16 
Bladder=12 
Melanoma=5 
Non melanoma skin cancer=8 
Lymphoma=11 
Endocrine=7 
Non Hodgkin Lymphoma=11 
Hodgkin disease=2 
Multiple Myeloma=11 
Chronic Lymphoid leukemia=6 
Myeloid leukemia=8 
Other leukemia=7 
Landgren, 2011   
 
USA Retrospective 
population-based 
study 
ICD on 
computer-
based file 
Patients 
hospitalized at 
Veterans 
Administratio
n Hospitals, 
across USA 
2810 57.67 
0 
≈12.02 
(≈33,776.2) 
All=85 (3.0) [0.2] 
Buccal cavity=85 
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Mellemkjaer, 1996  
 
Denmark Retrospective  ICD on 
computer-
based file 
Patients traced from 
nationwide Hospital 
Discharge Register in 
Denmark 
5072 71 for male; 73 
for female 
66 
5.1 (1-15) 
(25,767.2) 
All=295 (5.8) [1.1] 
CNS=7 
Buccal cavity and pharynx=16 
Lung=45 
Breast=39 
Cervix=1 
Uterus=10 
Ovary=6 
Prostate=39 
Kidney=14 
Bladder=23 
Melanoma=4 
Non melanoma skin cancer=57 
Non Hodgkin Lymphoma=14 
Multiple myeloma=7 
Leukemia=13 
 
Mosbech, 1950  
 
 
Denmark retrospective BT  
Ach 
Patients  hospitalized 
for PA and followed-
up as outpatients 
301 56.4 for male; 
59.1 for female 
72.7 
10.3 for 
male 
10.7 for 
female 
(3,190.6) 
All=4 (1.3) [0.1] 
Thyroid=1 
Breast=1 
Cervix uteri=1 
Prostate=1 
Siurala, 1966 
 
Finland Prospective BT  
Ach 
ST 
Outpatients referred to 
Hematological 
Department 
100  10-15 
(1,250) 
All=4 (4.0) [0.3] 
Thyroid=1 
Lung=2 
Leukemia=1 
OVERALL 
 
 
    45,373  150,2 
(6,825,006.6
6) 
ALL=1.194 (2.6) [0.02] 
 
Table 5 - Characteristics of the included studies reporting non-GI cancers. PA: pernicious anemia; ns: not specified; na: 
not applicable; nr: not reported; *duration from the time of PA diagnosis; §Cancer type not specified; ST: Schilling test; BT: 
Blood test; BM: bone marrow; Ach: achlorhydria;  EGD: gastroscopy. 34 and 12 cancer cases reported from Blackburn (1967) 
and van Knorre (1975), respectively, were excluded because it was not specified if GI or extra-GI cases. 
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Organ System Cases of 
cancer/PA patients 
(cumulative 
incidence %) 
[annual incidence 
rate per 100.000 
person-years] 
Organ Cases of cancer/PA 
patients (cumulative 
incidence %)[annual 
incidence rate per 
100.000 person-
years] 
References 
CNS 
 
 
25/15.155 (0.2) [5.7]  Brain and meninges  25/15.155 (0.2) [5.7] 1 Arvanitakis, 6 Brinton, 1 Chan, 10 Hsing, 7 
Mellemkjaer 
Maxillo-facial  
 
 
 
 
206/30.042 (0.7) [8.4]  Sinus maxillary 2/276 (0.7) [17.3] 1 Arvanitakis, 1 Demmler 
Eye 1/1561 (0.06) [2.8] 1 Brinton 
Buccal cavity and pharynx 203/30.004 (0.7) [9.1] 50 Brinton, 1 Chan, 1 Demmler, 34 Hemminki, 16 
Hsing, 85 Landgren, 16 Mellemkjaer 
Respiratory 
 
 
 
180/15.575 (1.2) [13.6] Larynx 2/4.555 (0.04) [3.4] 1 Arvanitakis, 1 Hsing,  
 
Lung 165/15.537 (1.1) [13.6] 80 Brinton, 7 Chan, 5 Demmler, 1 Elsborg, 25 Hsing, 
45 Mellemkjaer, 2 Siurala  
Other  13/5.161 (0.2) [37.0] 13 Brinton 
Endocrine  
 
 
 
12/10.190 (0.1) [2.4] Thyroid 5/5.673 (0.1) [2.0] 1 Ambrecht, 1 Arvanitakis, 1 Brinton, 1 Mosbech, 1 
Siurala 
Other 7/4.517 (0.1) [26.3] 7 Hsing 
GI other than gastric 
 
 
767/67.654 (1.1) [8.2] Esophagus 141/50.902 (0.3) [3.6] 11 Brinton, 1 Demmler, 26 Hemminki, 15 Hsing, 30 
Landgren, 8 Mellemkjaer, 50 Ye 
Small Bowel 19/24.753 (0.08) [1.1] 1 Brinton, 1 Chan, 1 Demmler, 9 Hemminki, 5 
Landgren, 2 Mellemkjaer 
Colon  271/30.789 (0.9) [10.3] 1 Armbrecht, 4 Borch, 34 Brinton, 4 Chan, 72 
Hemminki, 1 Hoffman, 36 Hsing, 59 Landgren, 50 
Mellemkjaer, 1 Mosbech, 9 Talley  
Rectum 121/30.036 (0.4) [4.8] 1 Arvanitakis, 1 Borch, 1 Brinton, 1 Demmler, 35 
Hemminki, 25 Hsing, 38 Landgren, 19 Mellemkjaer,  
Anus 3/11.839 (0.02) [4.4] 3 Hemminki 
Liver 40/18.589 (0.2) [4.2] 1 Borch, 2 Brinton, 1 Chan, 14 Hsing, 18 Landgren, 3 
Mellemkjaer, 1 Mosbech,  
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Biliary tract 30/15.478 (0.2) [6.7] 1 Borch, 4 Brinton, 1Chan, 18 Hsing, 6 Mellemkjaer  
Pancreas 123/33.483 (0.4) [4.8] 5 Borch, 7 Brinton, 3 Demmler, 34 Hsing, 25 Landgren, 
19 Mellemkjaer, 30 Shah  
Other 19/5.522 (0.4) [24.9] 17 Borch, 2 Brinton 
Female reproductive  
 
 
126/15.656 (0.8) [11.9] Breast 79/15.656 (0.5) [7.5] 1 Brinton, 1 Chan, 1 Demmler, 36 Hsing, 39 
Mellemkjaer, 1 Mosbech 
Uterus 31/10.495 (0.3) [4.9] 2 Chan, 1 Demmler, 16 Hsing, 11 Mellemkjaer, 1 
Mosbech 
Ovary 16/9.827 (0.2) [3.5] 1 Demmler, 9 Hsing, 6 Mellemkjaer  
Male reproductive  
 
 
191/15.189 (1.3) [31.9] Prostate 191/15.189 (1.3) [31.9] 90 Brinton, 3 Hoffman, 58 Hsing, 39 Mellemkjaer, 1 
Mosbech  
Urinary  
 
101/20.149 (0.5) [8.4] Kidney 41/14.988 (0.3) [5.2] 10 Brinton, 1 Demmler, 16 Hsing, 14 Mellemkjaer  
Bladder 60/14.988 (0.4) [7.6] 24 Brinton, 1 Demmler, 12 Hsing, 23 Mellemkjaer, 
Hematopoietic  
 
199/29.713 (0.7) [10.0] Hodgkin Lymphoma 3/9.678 (0.03) [2.4] 1 Brinton, 2 Hsing 
Non Hodgkin Lymphoma 70/22.240 (0.3) [15.4] 45 Fallah, 11 Hsing, 14 Mellemmkjaer  
Multiple Myeloma 28/14.888 (0.2) [6.5] 9 Brinton, 1 Hoffman, 11 Hsing, 7 Mellemkjaer, 
Leukemia 76/16.557 (0.5) [10.8] 9 Blackburn, 31 Brinton, 1 Elsborg, 21 Hsing, 13 
Mellemkjaer, 1 Siurala 
Other 22/11.808 (0.2) [6.1] 1 Blackburn, 6 Brinton, 2 Chan, 2 Hoffman, 11 Hsing 
Skin 86/14.750 (0.6) [32.8] Melanoma 21/14.750 (0.1) [8.0] 12 Brinton, 5 Hsing, 4 Mellemkjaer 
Non melanoma 65/9.589 (0.7) [61.6] 8 Hsing, 57 Mellemkjaer 
Bone and soft tissue 13/5.766 (0.2) [4.9] Bone 6/5.161 (0.1) [17.1] 6 Brinton 
Connective/soft tissue 7/5.766 (0.1) [2.6] 5 Brinton, 1 Chan, 1 Demmler 
 
Table 6 - Cancer incidence per organ system in PA patients. Cancer cases not included: 1 kidney/lymphoma/neurinoma 
(Arvanitakis); 3 genital (not specified if female or male from Brinton); 24 not specified (Borch); 26 not specified (Brinton); 44 not 
specified (Blackburn); 1 metastatis (Demmler). 
 
